Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration.

التفاصيل البيبلوغرافية
العنوان:	Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration.
المؤلفون:	Traidl-Hoffmann C; Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg, Augsburg, Germany.; Institute of Environmental Medicine, Helmholtz Zentrum München, Augsburg, Germany.; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland., Afghani J; Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg, Augsburg, Germany., Akdis C; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland., Akdis M; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland., Aydin H; AbbVie Inc., North Chicago, Illinois, USA., Bärenfaller K; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland., Behrendt H; Center for Allergy and Environment (ZAUM), Technische Universität München, Germany., Bieber T; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.; Davos Biosciences, Davos, Switzerland., Bigliardi P; University of Minnesota, Minneapolis, Minnesota, USA., Bigliardi-Qi M; University of Minnesota, Minneapolis, Minnesota, USA., Bonefeld CM; Department of Immunology and Microbiology, The LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark., Bösch S; Department of Dermatology, Allergy Unit, University Hospital of Zürich, Zürich, Switzerland.; Faculty of Medicine, University of Zürich, Zürich, Switzerland., Brüggen MC; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.; Department of Dermatology, Allergy Unit, University Hospital of Zürich, Zürich, Switzerland.; Faculty of Medicine, University of Zürich, Zürich, Switzerland., Diemert S; Almirall Hermal GmbH, Reinbek, Germany., Duchna HW; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.; Hochgebirgsklinik Davos, Davos, Switzerland., Fähndrich M; LEO Pharmaceutical Products Sarath Ltd, Zürich, Switzerland., Fehr D; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.; Department of Dermatology, Allergy Unit, University Hospital of Zürich, Zürich, Switzerland.; Faculty of Medicine, University of Zürich, Zürich, Switzerland., Fellmann M; Pfizer Switzerland AG, Zürich, Switzerland., Frei R; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.; Department of Pediatrics, Division of Respiratory Medicine and Allergology, Bern University Hospital, Bern, Switzerland.; Department of BioMedical Research (DBMR), University of Bern, Bern, Switzerland., Garvey LH; Department of Dermatology and Allergy, Allergy Clinic, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Gharbo R; Psychosomatic Department, Hochgebirgsklinik, Davos, Switzerland., Gökkaya M; Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg, Augsburg, Germany.; Institute of Environmental Medicine, Helmholtz Zentrum München, Augsburg, Germany., Grando K; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.; Department of Dermatology, Allergy Unit, University Hospital of Zürich, Zürich, Switzerland.; Faculty of Medicine, University of Zürich, Zürich, Switzerland., Guillet C; Department of Dermatology, Allergy Unit, University Hospital of Zürich, Zürich, Switzerland.; Faculty of Medicine, University of Zürich, Zürich, Switzerland., Guler E; Pfizer, Istanbul, Turkey., Gutermuth J; Universitair Ziekenhuis, Brussel, Belgium., Herrmann N; Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany., Hijnen DJ; Diakonessenhuis Utrecht Zeist Doorn Locatie Utrecht, Erasmus MC, University Medical Center Utrecht, Utrecht, Netherlands., Hülpüsch C; Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg, Augsburg, Germany.; Institute of Environmental Medicine, Helmholtz Zentrum München, Augsburg, Germany.; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland., Irvine AD; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland., Jensen-Jarolim E; Center of Pathophysiology, Infectiology and Immunology, Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.; The interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria., Kong HH; Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA., Koren H; Environmental Health, LLC, Durham, North Carolina, USA., Lang CCV; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.; Department of Immunology and Microbiology, The LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark.; Department of Dermatology, Allergy Unit, University Hospital of Zürich, Zürich, Switzerland., Lauener R; Ostschweizer Kinderspital St. Gallen, St.Gallen, Switzerland., Maintz L; Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany., Mantel PY; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland., Maverakis E; Department of Dermatology, University of California Davis, Sacramento, California, USA., Möhrenschlager M; Hochgebirgsklinik Davos, Davos, Switzerland., Müller S; Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany., Nadeau K; Stanford University School of Medicine, Stanford, California, USA., Neumann AU; Institute of Environmental Medicine and Integrative Health, Faculty of Medicine, University of Augsburg, Augsburg, Germany.; Institute of Environmental Medicine, Helmholtz Zentrum München, Augsburg, Germany., O'Mahony L; APC Microbiome Ireland, University College Cork, Cork, Ireland.; Department of Medicine and School of Microbiology, University College Cork, Cork, Ireland., Rabenja FR; Faculty of Médicine, Antananarivo, Madagascar., Renz H; Institute of Laboratory Medicine, Philipps University, Marburg, Germany., Rhyner C; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland., Rietschel E; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland., Ring J; Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technische Universität München, Munich, Germany., Roduit C; Department of Pediatrics, Division of Respiratory Medicine and Allergology, Bern University Hospital, Bern, Switzerland.; Ostschweizer Kinderspital St. Gallen, St.Gallen, Switzerland., Sasaki M; Department of Pediatrics, Division of Respiratory Medicine and Allergology, Bern University Hospital, Bern, Switzerland., Schenk M; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland., Schröder J; Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Schleswig-Holstein (UK-SH), Kiel, Germany., Simon D; Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Simon HU; Institute of Pharmacology, University of Bern, Bern, Switzerland.; Institute of Biochemistry, Brandenburg Medical School, Neuruppin, Germany., Sokolowska M; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland., Ständer S; Center for Chronic Pruritus and Department of Dermatology, University Hospital Münster, Münster, Germany., Steinhoff M; Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.; Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.; Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.; School of Medicine, Weill Cornell Medicine-Qatar, Ar-Rayyan, Qatar.; College of Medicine, Qatar University, Doha, Qatar.; College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, Qatar.; Department of Dermatology, Weill Cornell Medicine, New York, New York, USA., Piccirillo DS; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland., Taïeb A; INSERM 1312, University of Bordeaux, Bordeaux, France., Takaoka R; Department of Dermatology, Faculdade de Medicina, Hospital das Clínicas, Universidade de São Paulo, São Paulo, São Paulo, Brazil., Tapparo M; Bencard Allergie GmbH München, Munich, Germany., Teixeira H; Universitair Ziekenhuis, Brussel, Belgium., Thyssen JP; Department of Dermatology and Venerology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark., Traidl S; Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.; Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany., Uhlmann M; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland., van de Veen W; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland., van Hage M; Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institute and Karolinska University Hospital Stockholm, Solna, Sweden., Virchow C; Department of Pneumology, Intensive Care Medicine, Center for Internal Medicine, Universitätsmedizin Rostock, Rostock, Germany., Wollenberg A; Department of Dermatology and Allergy, Ludwig-Maximilian-University, Munich, Germany.; Department of Dermatology and Allergy, University Hospital Augsburg, Augsburg, Germany.; Comprehensive Center of Inflammation Medicine, University Hospital Schleswig Holstein Campus Luebeck, Lubeck, Germany., Yasutaka M; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Zurich, Switzerland., Zink A; Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany.; Department of Medicine Solna, Division of Dermatology and Venereology, Karolinska Institutet, Stockholm, Sweden., Schmid-Grendelmeier P; Christine Kühne-Center for Allergy Research and Education (CK-CARE), Medicine Campus, Davos, Switzerland.; Department of Immunology and Microbiology, The LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark.; Department of Dermatology, Allergy Unit, University Hospital of Zürich, Zürich, Switzerland.
المصدر:	Allergy [Allergy] 2024 Aug 04. Date of Electronic Publication: 2024 Aug 04.
Publication Model:	Ahead of Print
نوع المنشور:	Journal Article; Review
اللغة:	English
بيانات الدورية:	Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1398-9995 (Electronic) Linking ISSN: 01054538 NLM ISO Abbreviation: Allergy Subsets: MEDLINE
أسماء مطبوعة:	Publication: Copenhagen : Wiley-Blackwell Original Publication: Copenhagen, Munksgaard.
مستخلص:	The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient-centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to collaborate to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world. (© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
References:	Ring J, Akdis C, Behrendt H, et al. Davos declaration: allergy as a global problem. Allergy. 2012;67(2):141‐143. doi:10.1111/j.1398-9995.2011.02770.x. Ring J, Akdis C, Lauener R, Schäppi G, et al. Global allergy forum and second Davos declaration 2013 allergy: barriers to cure—challenges and actions to be taken. Allergy. 2014;69(8):978‐982. doi:10.1111/all.12406. Bieber T, Akdis C, Lauener R, Traidl‐Hoffmann C, et al. Global allergy forum and 3rd Davos declaration 2015: atopic dermatitis/eczema: challenges and opportunities toward precision medicine. Allergy. 2016;71(5):588‐592. doi:10.1111/all.12857. Elezbawy B, Fasseeh AN, Fouly E, Tannira M, et al. Humanistic and economic burden of atopic dermatitis for adults and adolescents in the Middle East and Africa region. Dermatol Ther. 2023;13(1):131‐146. doi:10.1007/s13555-022-00857-0. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21‐40. doi:10.1038/s41573-021-00266-6. Geba GP, Li D, Xu M, et al. Attenuating the atopic march: meta‐analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151(3):756‐766. doi:10.1016/j.jaci.2022.08.026. Lunjani N, Ambikan AT, Hlela C, et al. Rural and urban exposures shape early life immune development in south African children with atopic dermatitis and nonallergic children. Allergy. 2023;79:65‐79. doi:10.1111/all.15832. Pawankar R, Akdis CA. Climate change and the epithelial barrier theory in allergic diseases: a one health approach to a green environment. Allergy. 2023;78(11):2829‐2834. doi:10.1111/all.15885. Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22(8):662‐680. doi:10.1038/s41573-023-00735-0. Mitamura Y, Ogulur I, Pat Y, et al. Dysregulation of the epithelial barrier by environmental and other exogenous factors. Contact Derm. 2021;85(6):615‐626. doi:10.1111/cod.13959. Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Epithelial barrier hypothesis: effect of the external exposome on the microbiome and epithelial barriers in allergic disease. Allergy. 2022;77(5):1418‐1449. doi:10.1111/all.15240. Trautmann A, Akdis M, Kleemann D, et al. T cell‐mediated Fas‐induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest. 2000;106(1):25‐35. doi:10.1172/JCI9199. Stefanovic N, Irvine AD. Filaggrin and beyond: new insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives. Ann Allergy Asthma Immunol. 2023;132:187‐195. doi:10.1016/j.anai.2023.09.009. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280‐291. doi:10.1016/j.jaci.2012.12.668. Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol. 2021;21(11):739‐751. doi:10.1038/s41577-021-00538-7. Xian M, Wawrzyniak P, Rückert B, et al. Anionic surfactants and commercial detergents decrease tight junction barrier integrity in human keratinocytes. J Allergy Clin Immunol. 2016;138(3):890‐893.e9. doi:10.1016/j.jaci.2016.07.003. Tanzer J, Meng D, Ohsaki A, et al. Laundry detergent promotes allergic skin inflammation and esophageal eosinophilia in mice. PLoS One. 2022;17(6):e0268651. doi:10.1371/journal.pone.0268651. Rinnov MR, Halling AS, Gerner T, et al. Skin biomarkers predict development of atopic dermatitis in infancy. Allergy. 2023;78(3):791‐802. doi:10.1111/all.15518. Halling AS, Bager P, Skov L, et al. The interaction between filaggrin mutations and hard domestic water and the risk of early‐onset atopic dermatitis. Br J Dermatol. 2020;183(2):406‐407. doi:10.1111/bjd.18965. Renert‐Yuval Y, Del Duca E, Pavel AB, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021;148(1):148‐163. doi:10.1016/j.jaci.2021.01.001. Pavel AB, Renert‐Yuval Y, Wu J, et al. Tape strips from early‐onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. Allergy. 2021;76(1):314‐325. doi:10.1111/all.14490. Kortekaas Krohn I, Aerts JL, Breckpot K, et al. T‐cell subsets in the skin and their role in inflammatory skin disorders. Allergy. 2022;77(3):827‐842. doi:10.1111/all.15104. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R7‐R12. doi:10.1016/j.jaci.2009.07.012. Bieber T. Interleukin‐13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54‐62. doi:10.1111/all.13954. Tollenaere MAX, Litman T, Moebus L, et al. Skin barrier and inflammation genes associated with atopic dermatitis are regulated by interleukin‐13 and modulated by tralokinumab in vitro. Acta Derm Venereol. 2021;101(4):adv00447. doi:10.2340/00015555-3810. Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate‐to‐severe prurigo nodularis. N Engl J Med. 2020;382(8):706‐716. doi:10.1056/NEJMoa1908316. Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate‐to‐severe atopic dermatitis. N Engl J Med. 2014;371(2):130‐139. doi:10.1056/NEJMoa1314768. Berdyshev E, Goleva E, Bissonnette R, et al. Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis. Allergy. 2022;77(11):3388‐3397. doi:10.1111/all.15432. Beck LA, Bieber T, Weidinger S, et al. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate‐to‐severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. J Am Acad Dermatol. 2023;88(4):816‐823. doi:10.1016/j.jaad.2022.11.047. Rohner MH, Thormann K, Cazzaniga S, et al. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis. Allergy. 2021;76(4):1268‐1270. doi:10.1111/all.14664. Brough HA, Lanser BJ, Sindher SB, et al. Early intervention and prevention of allergic diseases. Allergy. 2022;77(2):416‐441. doi:10.1111/all.15006. Sindher SB, Long A, Chin AR, et al. Food allergy, mechanisms, diagnosis and treatment: innovation through a multi‐targeted approach. Allergy. 2022;77(10):2937‐2948. doi:10.1111/all.15418. Bangert C, Rindler K, Krausgruber T, et al. Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL‐4Rα blockade. Sci Immunol. 2021;6(55):eabe2749. doi:10.1126/sciimmunol.abe2749. Zhang B, Roesner LM, Traidl S, et al. Single‐cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis. Allergy. 2023;78(2):439‐453. doi:10.1111/all.15486. Naik S, Larsen SB, Gomez NC, et al. Inflammatory memory sensitizes skin epithelial stem cells to tissue damage. Nature. 2017;550(7677):475‐480. doi:10.1038/nature24271. Alkon N, Bauer W, Krausgruber T, et al. Single‐cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis. J Allergy Clin Immunol. 2022;149(2):624‐639. doi:10.1016/j.jaci.2021.07.025. Naik S, Fuchs E. Inflammatory memory and tissue adaptation in sickness and in health. Nature. 2022;607(7918):249‐255. doi:10.1038/s41586-022-04919-3. Gläser R, Harder J, Lange H, Bartels J, Christophers E, Schröder JM. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol. 2005;6(1):57‐64. doi:10.1038/ni1142. Murdoch CC, Skaar EP. Nutritional immunity: the battle for nutrient metals at the host‐pathogen interface. Nat Rev Microbiol. 2022;20(11):657‐670. doi:10.1038/s41579-022-00745-6. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151‐1160. doi:10.1056/NEJMoa021481. Harder J, Dressel S, Wittersheim M, et al. Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. J Invest Dermatol. 2010;130(5):1355‐1364. doi:10.1038/jid.2009.432. Traidl S, Roesner L, Zeitvogel J, Werfel T. Eczema herpeticum in atopic dermatitis. Allergy. 2021;76(10):3017‐3027. doi:10.1111/all.14853. Hata TR, Kotol P, Boguniewicz M, et al. History of eczema herpeticum is associated with the inability to induce human β‐defensin (HBD)‐2, HBD‐3 and cathelicidin in the skin of patients with atopic dermatitis. Br J Dermatol. 2010;163(3):659‐661. doi:10.1111/j.1365-2133.2010.09892.x. Latendorf T, Gerstel U, Wu Z, et al. Cationic intrinsically disordered antimicrobial peptides (CIDAMPs) represent a new paradigm of innate defense with a potential for novel anti‐infectives. Sci Rep. 2019;9(1):3331. doi:10.1038/s41598-019-39219-w. Niehues H, Tsoi LC, van der Krieken DA, et al. Psoriasis‐associated late cornified envelope (LCE) proteins have antibacterial activity. J Invest Dermatol. 2017;137(11):2380‐2388. doi:10.1016/j.jid.2017.06.003. Gerstel U, Latendorf T, Bartels J, Becker A, Tholey A, Schröder JM. Hornerin contains a linked series of ribosome‐targeting peptide antibiotics. Sci Rep. 2018;8(1):16158. doi:10.1038/s41598-018-34467-8. Deng L, Costa F, Blake KJ, et al. S. aureus drives itch and scratch‐induced skin damage through a V8 protease‐PAR1 axis. Cell. 2023;186(24):5375‐5393.e25. doi:10.1016/j.cell.2023.10.019. Shelley JR, McHugh BJ, Wills J, et al. A mechanistic evaluation of human beta defensin 2 mediated protection of human skin barrier in vitro. Sci Rep. 2023;13(1):2271. doi:10.1038/s41598-023-29558-0. Man K, Kutyavin VI, Chawla A. Tissue immunometabolism: development, physiology, and pathobiology. Cell Metab. 2017;25(1):11‐26. doi:10.1016/j.cmet.2016.08.016. Afghani J, Traidl‐Hoffmann C, Schmitt‐Kopplin P, Reiger M, Mueller C. An overview of the latest metabolomics studies on atopic eczema with new directions for study. Int J Mol Sci. 2022;23(15):8791. doi:10.3390/ijms23158791. Ottas A, Fishman D, Okas TL, et al. Blood serum metabolome of atopic dermatitis: altered energy cycle and the markers of systemic inflammation. PLoS One. 2017;12(11):e0188580. doi:10.1371/journal.pone.0188580. Martínez BA, Shrotri S, Kingsmore KM, Bachali P, Grammer AC, Lipsky PE. Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases. Sci Adv. 2022;8(17):eabn4776. doi:10.1126/sciadv.abn4776. Yin H, Qiu Z, Zhu R, et al. Dysregulated lipidome of sebum in patients with atopic dermatitis. Allergy. 2023;78(6):1524‐1537. doi:10.1111/all.15569. Zhang L, Wen X, Hou Y, et al. Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab. Front Immunol. 2022;13:1002536. doi:10.3389/fimmu.2022.1002536. Trompette A, Pernot J, Perdijk O, et al. Gut‐derived short‐chain fatty acids modulate skin barrier integrity by promoting keratinocyte metabolism and differentiation. Mucosal Immunol. 2022;15(5):908‐926. doi:10.1038/s41385-022-00524-9. Steinhoff M, Ahmad F, Pandey A, et al. Neuroimmune communication regulating pruritus in atopic dermatitis. J Allergy Clin Immunol. 2022;149(6):1875‐1898. doi:10.1016/j.jaci.2022.03.010. Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co‐opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217‐228.e13. doi:10.1016/j.cell.2017.08.006. Trier AM, Mack MR, Fredman A, et al. IL‐33 signaling in sensory neurons promotes dry skin itch. J Allergy Clin Immunol. 2022;149(4):1473‐1480.e6. doi:10.1016/j.jaci.2021.09.014. Keren A, Reich K, Bertolini M, et al. Autologous Th2‐polarized lymphocytes induce atopic dermatitis lesions in non‐atopic human skin xenotransplants. Allergy. 2023;78(6):1538‐1553. doi:10.1111/all.15635. Stefanovic N, Irvine AD, Flohr C. The role of the environment and exposome in atopic dermatitis. Curr Treat Options Allergy. 2021;8(3):222‐241. doi:10.1007/s40521-021-00289-9. Wang SP, Stefanovic N, Orfali RL, et al. Impact of climate change on atopic dermatitis: a review by the international eczema council. Allergy. 2024;79:1455‐1469. doi:10.1111/all.16007. Pfaar O, Klimek L, Jutel M, Akdis CA, et al. COVID‐19 pandemic: practical considerations on the organization of an allergy clinic‐an EAACI/ARIA position paper. Allergy. 2021;76(3):648‐676. doi:10.1111/all.14453. Fadadu RP, Green M, Jewell NP, Grimes B, Vargo J, Wei ML. Association of exposure to wildfire air pollution with exacerbations of atopic dermatitis and itch among older adults. JAMA Netw Open. 2022;5(10):e2238594. doi:10.1001/jamanetworkopen.2022.38594. Donald K, Finlay BB. Early‐life interactions between the microbiota and immune system: impact on immune system development and atopic disease. Nat Rev Immunol. 2023;23(11):735‐748. doi:10.1038/s41577-023-00874-w. Agache I, Sampath V, Aguilera J, et al. Climate change and global health: a call to more research and more action. Allergy. 2022;77(5):1389‐1407. doi:10.1111/all.15229. Perera F, Nadeau K. Climate change, fossil‐fuel pollution, and children's health. N Engl J Med. 2022;386(24):2303‐2314. doi:10.1056/NEJMra2117706. Kiewiet MBG, Grundström J, Apostolovic D, et al. Elucidating the α‐gal syndrome at the molecular allergen level. Allergy. 2021;76(5):1576‐1578. doi:10.1111/all.14660. Apostolovic D, Mihailovic J, Commins SP, et al. Allergenomics of the tick Ixodes ricinus reveals important α‐gal‐carrying IgE‐binding proteins in red meat allergy. Allergy. 2020;75(1):217‐220. doi:10.1111/all.13978. Apostolovic D, Tran TAT, Hamsten C, Starkhammar M, Cirkovic Velickovic T, van Hage M. Immunoproteomics of processed beef proteins reveal novel galactose‐α‐1,3‐galactose‐containing allergens. Allergy. 2014;69(10):1308‐1315. doi:10.1111/all.12462. Perusko M, Apostolovic D, Kiewiet MBG, et al. Bovine γ‐globulin, lactoferrin, and lactoperoxidase are relevant bovine milk allergens in patients with α‐gal syndrome. Allergy. 2021;76(12):3766‐3775. doi:10.1111/all.14889. Effner R, Hiller J, Eyerich S, et al. Cytochrome P450s in human immune cells regulate IL‐22 and c‐kit via an AHR feedback loop. Sci Rep. 2017;7:44005. doi:10.1038/srep44005. Zhao F, Elkelish A, Durner J, et al. Common ragweed (Ambrosia artemisiifolia L.): allergenicity and molecular characterization of pollen after plant exposure to elevated NO2. Plant Cell Environ. 2016;39(1):147‐164. doi:10.1111/pce.12601. Oeder S, Alessandrini F, Wirz OF, et al. Pollen‐derived nonallergenic substances enhance Th2‐induced IgE production in B cells. Allergy. 2015;70(11):1450‐1460. doi:10.1111/all.12707. El Kelish A, Zhao F, Heller W, et al. Ragweed (Ambrosia artemisiifolia) pollen allergenicity: SuperSAGE transcriptomic analysis upon elevated CO2 and drought stress. BMC Plant Biol. 2014;14:176. doi:10.1186/1471-2229-14-176. Beck I, Jochner S, Gilles S, et al. High environmental ozone levels lead to enhanced allergenicity of birch pollen. PLoS One. 2013;8(11):e80147. doi:10.1371/journal.pone.0080147. Ege MJ, Mayer M, Normand AC, et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med. 2011;364(8):701‐709. doi:10.1056/NEJMoa1007302. Jensen SA, Fiocchi A, Baars T, et al. Diagnosis and rationale for action against cow's milk allergy (DRACMA) guidelines update–III–cow's milk allergens and mechanisms triggering immune activation. World Allergy Organ J. 2022;15(9):100668. doi:10.1016/j.waojou.2022.100668. Deckers J, Lambrecht BN, Hammad H. How a farming environment protects from atopy. Curr Opin Immunol. 2019;60:163‐169. doi:10.1016/j.coi.2019.08.001. Bartosik T, Jensen SA, Afify SM, et al. Ameliorating atopy by compensating micronutritional deficiencies in immune cells: a double‐blind placebo‐controlled pilot study. J Allergy Clin Immunol Pract. 2022;10(7):1889‐1902.e9. doi:10.1016/j.jaip.2022.02.028. Bigliardi PL. Role of skin pH in psoriasis. Curr Probl Dermatol. 2018;54:108‐114. doi:10.1159/000489524. Hülpüsch C, Tremmel K, Hammel G, et al. Skin pH–dependent Staphylococcus aureus abundance as predictor for increasing atopic dermatitis severity. Allergy. 2020;75(11):2888‐2898. doi:10.1111/all.14461. Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):26‐35. doi:10.1016/j.jaci.2018.11.015. Halling AS, Fritz BG, Gerner T, et al. Reduced skin microbiome diversity in infancy is associated with increased risk of atopic dermatitis in high‐risk children. J Invest Dermatol. 2023;143(10):2030‐2038.e6. doi:10.1016/j.jid.2023.03.1682. Georgountzou A, Papadopoulos NG. Postnatal innate immune development: from birth to adulthood. Front Immunol. 2017;8:957. doi:10.3389/fimmu.2017.00957. Halling AS, Rinnov MR, Ruge IF, et al. Skin TARC/CCL17 increase precedes the development of childhood atopic dermatitis. J Allergy Clin Immunol. 2023;151(6):1550‐1557.e6. doi:10.1016/j.jaci.2022.11.023. Kawamoto N, Kaneko H, Takemura M, et al. Age‐related changes in intracellular cytokine profiles and Th2 dominance in allergic children. Pediatr Allergy Immunol. 2006;17(2):125‐133. doi:10.1111/j.1399-3038.2005.00363.x. Wang S, Zhu R, Gu C, et al. Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China. J Eur Acad Dermatol Venereol. 2020;34(10):2346‐2352. doi:10.1111/jdv.16346. Thyssen JP, Halling AS, Schmid‐Grendelmeier P, Guttman‐Yassky E, Silverberg JI. Comorbidities of atopic dermatitis‐what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155‐1162. doi:10.1016/j.jaci.2022.12.002. Tham EH, Rajakulendran M, Lee BW, Van Bever HPS. Epicutaneous sensitization to food allergens in atopic dermatitis: what do we know? Pediatr Allergy Immunol. 2020;31(1):7‐18. doi:10.1111/pai.13127. Wollenberg A, Thomsen SF, Lacour JP, Jaumont X, Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence. World Allergy Organ J. 2021;14(3):100519. doi:10.1016/j.waojou.2021.100519. Abuabara K, Ye M, McCulloch CE, et al. Clinical onset of atopic eczema: results from 2 nationally representative British birth cohorts followed through midlife. J Allergy Clin Immunol. 2019;144(3):710‐719. doi:10.1016/j.jaci.2019.05.040. Maintz L, Schmitz MT, Herrmann N, et al. Atopic dermatitis: correlation of distinct risk factors with age of onset in adulthood compared to childhood. Allergy. 2023;78(8):2181‐2201. doi:10.1111/all.15721. Kim D, Kobayashi T, Nagao K. Research techniques made simple: mouse models of atopic dermatitis. J Invest Dermatol. 2019;139(5):984‐990.e1. doi:10.1016/j.jid.2019.02.014. Jin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. J Invest Dermatol. 2009;129(1):31‐40. doi:10.1038/jid.2008.106. Marsella R. Atopic dermatitis in domestic animals: what our current understanding is and how this applies to clinical practice. Vet Sci. 2021;8(7):124. doi:10.3390/vetsci8070124. Maintz L, Welchowski T, Herrmann N, et al. Machine learning‐based deep phenotyping of atopic dermatitis: severity‐associated factors in adolescent and adult patients. JAMA Dermatol. 2021;157(12):1414‐1424. doi:10.1001/jamadermatol.2021.3668. Tan KJ, Nakamizo S, Lee‐Okada HC, et al. A Western diet alters skin ceramides and compromises the skin barrier in ears. J Invest Dermatol. 2022;142(7):2020‐2023.e2. doi:10.1016/j.jid.2021.12.017. Venter C, Palumbo MP, Sauder KA, et al. Associations between child filaggrin mutations and maternal diet with the development of allergic diseases in children. Pediatr Allergy Immunol. 2022;33(3):e13753. doi:10.1111/pai.13753. Venter C, Greenhawt M, Meyer RW, et al. EAACI position paper on diet diversity in pregnancy, infancy and childhood: novel concepts and implications for studies in allergy and asthma. Allergy. 2020;75(3):497‐523. doi:10.1111/all.14051. Jafferany M, Davari ME. Itch and psyche: psychiatric aspects of pruritus. Int J Dermatol. 2019;58(1):3‐23. doi:10.1111/ijd.14081. Grundmann S, Ständer S. Chronic pruritus: clinics and treatment. Ann Dermatol. 2011;23(1):1‐11. doi:10.5021/ad.2011.23.1.1. Darsow U, Drzezga A, Frisch M, et al. Processing of histamine‐induced itch in the human cerebral cortex: a correlation analysis with dermal reactions. J Invest Dermatol. 2000;115(6):1029‐1033. doi:10.1046/j.1523-1747.2000.00193.x. Trier AM, Mack MR, Kim BS. The neuroimmune axis in skin sensation, inflammation, and immunity. J Immunol. 2019;202(10):2829‐2835. doi:10.4049/jimmunol.1801473. Ekblom A, Lundeberg T, Wahlgren CF. Influence of calcitonin gene‐related peptide on histamine‐ and substance P‐induced itch, flare and weal in humans. Skin Pharmacol. 1993;6(3):215‐222. doi:10.1159/000211138. Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013;14(11):1289‐1303. doi:10.1016/j.jpain.2013.03.010. Steinhoff M, Buddenkotte J, Lerner EA. Role of mast cells and basophils in pruritus. Immunol Rev. 2018;282(1):248‐264. doi:10.1111/imr.12635. Graham HT, Lowry OH, Wahl N, Priebat MK. Mast cells as sources of tissue histamine. J Exp Med. 1955;102(3):307‐318. doi:10.1084/jem.102.3.307. Malaviya R, Morrison AR, Pentland AP. Histamine in human epidermal cells is induced by ultraviolet light injury. J Invest Dermatol. 1996;106(4):785‐789. doi:10.1111/1523-1747.ep12346356. Wang F, Yang TLB, Kim BS. The return of the mast cell: new roles in neuroimmune itch biology. J Invest Dermatol. 2020;140(5):945‐951. doi:10.1016/j.jid.2019.12.011. Wang F, Trier AM, Li F, et al. A basophil‐neuronal axis promotes itch. Cell. 2021;184(2):422‐440.e17. doi:10.1016/j.cell.2020.12.033. Kaur G, Singh N, Jaggi AS. Mast cells in neuropathic pain: an increasing spectrum of their involvement in pathophysiology. Rev Neurosci. 2017;28(7):759‐766. doi:10.1515/revneuro-2017-0007. Kushnir‐Sukhov NM, Brown JM, Wu Y, Kirshenbaum A, Metcalfe DD. Human mast cells are capable of serotonin synthesis and release. J Allergy Clin Immunol. 2007;119(2):498‐499. doi:10.1016/j.jaci.2006.09.003. Toru H, Pawankar R, Ra C, Yata J, Nakahata T. Human mast cells produce IL‐13 by high‐affinity IgE receptor cross‐linking: enhanced IL‐13 production by IL‐4‐primed human mast cells. J Allergy Clin Immunol. 1998;102(3):491‐502. doi:10.1016/s0091-6749(98)70140-x. Bradding P, Feather IH, Howarth PH, et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med. 1992;176(5):1381‐1386. doi:10.1084/jem.176.5.1381. Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. J Exp Med. 1995;181(4):1373‐1380. doi:10.1084/jem.181.4.1373. Furue M, Yamamura K, Kido‐Nakahara M, Nakahara T, Fukui Y. Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis. Allergy. 2018;73(1):29‐36. doi:10.1111/all.13239. Wilson SR, Thé L, Batia LM, et al. The epithelial cell‐derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell. 2013;155(2):285‐295. doi:10.1016/j.cell.2013.08.057. Ständer S, Gunzer M, Metze D, Luger T, Steinhoff M. Localization of mu‐opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept. 2002;110(1):75‐83. doi:10.1016/s0167-0115(02)00159-3. Pfab F, Kirchner MT, Huss‐Marp J, et al. Acupuncture compared with oral antihistamine for type I hypersensitivity itch and skin response in adults with atopic dermatitis: a patient‐ and examiner‐blinded, randomized, placebo‐controlled, crossover trial. Allergy. 2012;67(4):566‐573. doi:10.1111/j.1398-9995.2012.02789.x. Stumpf A, Zerey V, Heuft G, Ständer S, Pfleiderer B, Schneider G. Itch perception and skin reactions as modulated by verbal suggestions: role of participant's and investigator's sex. Acta Derm Venereol. 2016;96(5):619‐623. doi:10.2340/00015555-2336. Bartels DJP, van Laarhoven AIM, Stroo M, et al. Minimizing nocebo effects by conditioning with verbal suggestion: a randomized clinical trial in healthy humans. PLoS One. 2017;12(9):e0182959. doi:10.1371/journal.pone.0182959. Stumpf A, Schneider G, Ständer S. Psychosomatic and psychiatric disorders and psychologic factors in pruritus. Clin Dermatol. 2018;36(6):704‐708. doi:10.1016/j.clindermatol.2018.08.015. Dalgard FJ, Gieler U, Tomas‐Aragones L, et al. The psychological burden of skin diseases: a cross‐sectional multicenter study among dermatological out‐patients in 13 European countries. J Invest Dermatol. 2015;135(4):984‐991. doi:10.1038/jid.2014.530. Dieris‐Hirche J, Gieler U, Kupfer JP, Milch WE. Suicidal ideation, anxiety and depression in adult patients with atopic dermatitis. Hautarzt. 2009;60(8):641‐646. doi:10.1007/s00105-009-1744-y. Roesner LM, Farag AK, Pospich R, Traidl S, Werfel T. T‐cell receptor sequencing specifies psoriasis as a systemic and atopic dermatitis as a skin‐focused, allergen‐driven disease. Allergy. 2022;77(9):2737‐2747. doi:10.1111/all.15272. Ascott A, Mulick A, Yu AM, et al. Atopic eczema and major cardiovascular outcomes: a systematic review and meta‐analysis of population‐based studies. J Allergy Clin Immunol. 2019;143(5):1821‐1829. doi:10.1016/j.jaci.2018.11.030. Thyssen JP, Halling‐Overgaard AS, Andersen YMF, Gislason G, Skov L, Egeberg A. The association with cardiovascular disease and type 2 diabetes in adults with atopic dermatitis: a systematic review and meta‐analysis. Br J Dermatol. 2018;178(6):1272‐1279. doi:10.1111/bjd.16215. Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ. 2018;361:k1786. doi:10.1136/bmj.k1786. Park JH, Jeong DY, Peyrin‐Biroulet L, Eisenhut M, Shin JI. Insight into the role of TSLP in inflammatory bowel diseases. Autoimmun Rev. 2017;16(1):55‐63. doi:10.1016/j.autrev.2016.09.014. Nemmer JM, Kuchner M, Datsi A, et al. Interleukin‐31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med. 2021;8:639097. doi:10.3389/fmed.2021.639097. Anzelc M, Burkhart CG. Pain and pruritus: a study of their similarities and differences. Int J Dermatol. 2020;59(2):159‐164. doi:10.1111/ijd.14678. Chiu IM, Heesters BA, Ghasemlou N, et al. Bacteria activate sensory neurons that modulate pain and inflammation. Nature. 2013;501(7465):52‐57. doi:10.1038/nature12479. Mohr N, Augustin M, Zeervi L, et al. Determinants of costs and benefits in atopic dermatitis routine care in Germany. J Eur Acad Dermatol Venereol. 2022;36(9):1450‐1455. doi:10.1111/jdv.18169. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I–systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409‐1431. doi:10.1111/jdv.18345. Bieber T, Paller AS, Kabashima K, et al. Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. J Eur Acad Dermatol Venereol. 2022;36(9):1432‐1449. doi:10.1111/jdv.18225. Wollenberg A, Kinberger M, Arents B, et al. First update of the living European guideline (EuroGuiDerm) on atopic eczema. J Eur Acad Dermatol Venereol. 2023;37(11):e1283‐e1287. doi:10.1111/jdv.19269. Silverberg JI, Guttman‐Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate‐to‐severe atopic dermatitis. N Engl J Med. 2023;388(12):1080‐1091. doi:10.1056/NEJMoa2206714. Drucker AM, Morra DE, Prieto‐Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta‐analysis. JAMA Dermatol. 2022;158(5):523‐532. doi:10.1001/jamadermatol.2022.0455. Davis DMR, Drucker AM, Alikhan A, et al. American Academy of Dermatology guidelines: awareness of comorbidities associated with atopic dermatitis in adults. J Am Acad Dermatol. 2022;86(6):1335‐1336.e18. doi:10.1016/j.jaad.2022.01.009. Akdis CA, Akdis M, Boyd SD, Sampath V, Galli SJ, Nadeau KC. Allergy: mechanistic insights into new methods of prevention and therapy. Sci Transl Med. 2023;15(679):eadd2563. doi:10.1126/scitranslmed.add2563. De Bruin‐Weller M, Biedermann T, Bissonnette R, et al. Treat‐to‐target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402. doi:10.2340/00015555-3751. Williams HC, Schmitt J, Thomas KS, et al. The HOME core outcome set for clinical trials of atopic dermatitis. J Allergy Clin Immunol. 2022;149(6):1899‐1911. doi:10.1016/j.jaci.2022.03.017. Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136‐1143. doi:10.1056/NEJMra2023911. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z. Czarnowicki T, He H, Krueger JG, Guttman‐Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1‐11. doi:10.1016/j.jaci.2018.10.032. Brunner PM, He H, Pavel AB, et al. The blood proteomic signature of early‐onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long‐standing disease. J Am Acad Dermatol. 2019;81(2):510‐519. doi:10.1016/j.jaad.2019.04.036. Maintz L, Welchowski T, Herrmann N, et al. IL‐13, periostin and dipeptidyl‐peptidase‐4 reveal endotype‐phenotype associations in atopic dermatitis. Allergy. 2023;17. doi:10.1111/all.15647. Renert‐Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis‐a review on behalf of the international eczema council. J Allergy Clin Immunol. 2021;147(4):1174‐1190.e1. doi:10.1016/j.jaci.2021.01.013. Wollenberg A, Howell MD, Guttman‐Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti‐IL‐13 mAb. J Allergy Clin Immunol. 2019;143(1):135‐141. doi:10.1016/j.jaci.2018.05.029. Ungar B, Garcet S, Gonzalez J, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603‐613. doi:10.1016/j.jid.2016.09.037. Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol. 2014;133(6):1626‐1634. doi:10.1016/j.jaci.2014.03.003. Bakker DS, Ariens LFM, Giovannone B, et al. EASI p‐EASI: predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. Allergy. 2020;75(12):3287‐3289. doi:10.1111/all.14492. Olydam JI, de Wijs LEM, Dik WA, Røpke MA, Da Rosa JC, Hijnen DJ. EASI p‐EASI: predicting disease severity in patients with atopic dermatitis treated with tralokinumab. J Invest Dermatol. 2022;142(12):3335‐3337.e1. doi:10.1016/j.jid.2022.06.008. Thijs JL, Drylewicz J, Bruijnzeel‐Koomen CAFM, et al. EASI p‐EASI: predicting disease severity in atopic dermatitis patients treated with cyclosporin A. Allergy. 2019;74(3):613‐617. doi:10.1111/all.13651. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema–part II: non‐systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904‐1926. doi:10.1111/jdv.18429. Akinlade B, Guttman‐Yassky E, de Bruin‐Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459‐473. doi:10.1111/bjd.17869. Halling AS, Loft N, Silverberg JI, Guttman‐Yassky E, Thyssen JP. Real‐world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta‐analysis. J Am Acad Dermatol. 2021;84(1):139‐147. doi:10.1016/j.jaad.2020.08.051. Lang CCV, Renert‐Yuval Y, Del Duca E, et al. Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients. Ann Allergy Asthma Immunol. 2021;127(3):334‐341. doi:10.1016/j.anai.2021.04.023. Brunner PM, Guttman‐Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(5):449‐455. doi:10.1016/j.anai.2018.11.015. Thyssen JP, Vestergaard C, Deleuran M, et al. European task force on atopic dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(12):e839‐e842. doi:10.1111/jdv.16716. Bieber T. In search of the holy grail in atopic dermatitis: will dupilumab become the first disease‐modifying atopic dermatitis drug? J Allergy Clin Immunol. 2023;151(3):694‐696. doi:10.1016/j.jaci.2022.12.824. Thyssen JP, Schmid‐Grendelmeier P. Long‐term disease control in atopic dermatitis using biologics. Lancet. 2023;401(10372):172‐173. doi:10.1016/S0140-6736(22)02347-9. Schmid‐Grendelmeier P, Rapelanoro Rabenja F, Beshah AM, et al. How to integrate atopic dermatitis in the management of skin neglected tropical diseases in sub‐Saharan Africa? J Eur Acad Dermatol Venereol. 2023;37:e1040‐e1042. doi:10.1111/jdv.19096. Herrmann A, Lenzer B, Müller BS, et al. Integrating planetary health into clinical guidelines to sustainably transform health care. Lancet Planet Health. 2022;6(3):e184‐e185. doi:10.1016/S2542-5196(22)00041-9. The International Eczema Council, The International Society for Atopic Dermatitis, The European Taskforce for Atopic Dermatitis, The International League of Dermatological Societies, The International Alliance of Dermatology Patient Organizations (Global Skin). The Global Atopic Dermatitis Atlas. Accessed December 18, 2023. https://www.eczemacouncil.org/global‐atopic‐dermatitis‐atlas. Heratizadeh A, Werfel T, Wollenberg A, et al. Effects of structured patient education in adults with atopic dermatitis: multicenter randomized controlled trial. J Allergy Clin Immunol. 2017;140(3):845‐853.e3. doi:10.1016/j.jaci.2017.01.029. Traidl S, Lang C, Schmid‐Grendelmeier P, Werfel T, Heratizadeh A. Comprehensive approach: current status on patient education in atopic dermatitis and other allergic diseases. Handb Exp Pharmacol. 2022;268:487‐500. doi:10.1007/164_2021_488. Gerth van Wijk R, Mülleneisen N, Demoly P, et al. The roadmap for allergology in Europe: the European training requirements for the specialty of allergology. Allergy. 2021;76(5):1588‐1591. doi:10.1111/all.14614. Goi HC, Tan WL. Design thinking as a means of citizen science for social innovation. Front Sociol. 2021;6:629808. doi:10.3389/fsoc.2021.629808. Straub Piccirillo D, Schmid‐Grendelmeier P, Hitzler M, Lauener R. Continuing medical education activities for improved management of allergy patients. Allergy. 2018;73(6):1351‐1353. doi:10.1111/all.13443. Guest C, Wainwright P, Herbert M, Smith IM. Driving quality improvement with a massive open online course (MOOC). BMJ Open Qual. 2021;10(1):e000781. doi:10.1136/bmjoq-2019-000781. Nieder J, Nayna Schwerdtle P, Sauerborn R, Barteit S. Massive open online courses for health worker education in low‐ and middle‐income countries: a scoping review. Front Public Health. 2022;10:891987. doi:10.3389/fpubh.2022.891987. Gudmundsdóttir SL, Ballarini T, Ámundadóttir ML, et al. Engagement, retention, and acceptability in a digital health program for atopic dermatitis: prospective interventional study. JMIR Form Res. 2023;7:e41227. doi:10.2196/41227. Kiani C, Steiner C, Zink A. Smart skin‐a new technology in the area of digital dermatology. Dermatologie (Heidelb). 2022;73(11):891‐900. doi:10.1007/s00105-022-05066-6.
فهرسة مساهمة:	Keywords: allergy treament; atopic dermatitis; barrier; environment; hygiene hypothesis
تواريخ الأحداث:	Date Created: 20240805 Latest Revision: 20240805
رمز التحديث:	20240805
DOI:	10.1111/all.16247
PMID:	39099205
قاعدة البيانات:	MEDLINE

View record at Wiley

Full Text Finder

الوصف
تدمد:	1398-9995
DOI:	10.1111/all.16247